• Je něco špatně v tomto záznamu ?

Molekulárně genetická diagnostika X-vázané formy Alportova syndromu
[Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples]

Tazón-Vega B, Ars E, Burset M, Santin S, Ruíz P, Fernandez-Llama P, Ballarin J, Torra R

. 2007 ; 5 (6) : 85.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07505976

Alport syndrome (AS) is a genetically heterogeneous hereditary renal disease. X-Linked AS (XLAS) is responsible for 80% to 85% of familial cases and is caused by mutations in the COL4A5 collagen gene. To date, indirect molecular diagnosis for XLAS is not well defined, and mutation screening of the COL4A5 gene is time consuming and complicated because of its large size and high allelic heterogeneity. Our aim is to facilitate XLAS genetic testing. METHODS: For linkage analysis, we tested the applicability of 4 microsatellite markers defining a 1.2-megabase region flanking the COL4A5 gene. For mutation screening of the COL4A5 gene, we describe a new strategy based on direct sequencing of hair root COL4A5 messenger RNA (mRNA). RESULTS: Three microsatellite markers proved accurate (DXS1120, DXS6802, and DXS1210) and 1 was discarded (DXS6797) because it was difficult to interpret. The mutation screening method provides results in 4 days, and when applied to 29 patients suspected of having XLAS, it identified mutations in 76% (22 of 29 patients). This study correlates COL4A5 mutations with effects at the mRNA level and suggests that mutations affecting mRNA splicing of the COL4A5 gene (41%; 9 of 22 patients) are more common than previously described. Many splicing mutations did not alter the canonical 5' and 3' splice sites. CONCLUSIONS: A more reliable linkage analysis and a simple, fast, and efficient mutation screening are now available for the genetic testing of patients with XLAS.

Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples

000      
03731naa 2200505 a 4500
001      
bmc07505976
003      
CZ-PrNML
005      
20111210122452.0
008      
080627s2007 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Tazón-Vega, B.
245    10
$a Molekulárně genetická diagnostika X-vázané formy Alportova syndromu / $c Tazón-Vega B, Ars E, Burset M, Santin S, Ruíz P, Fernandez-Llama P, Ballarin J, Torra R
246    11
$a Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples
314    __
$a Molecular Biology Laboratory, Fundació Puigvert, Barcelona
520    9_
$a Alport syndrome (AS) is a genetically heterogeneous hereditary renal disease. X-Linked AS (XLAS) is responsible for 80% to 85% of familial cases and is caused by mutations in the COL4A5 collagen gene. To date, indirect molecular diagnosis for XLAS is not well defined, and mutation screening of the COL4A5 gene is time consuming and complicated because of its large size and high allelic heterogeneity. Our aim is to facilitate XLAS genetic testing. METHODS: For linkage analysis, we tested the applicability of 4 microsatellite markers defining a 1.2-megabase region flanking the COL4A5 gene. For mutation screening of the COL4A5 gene, we describe a new strategy based on direct sequencing of hair root COL4A5 messenger RNA (mRNA). RESULTS: Three microsatellite markers proved accurate (DXS1120, DXS6802, and DXS1210) and 1 was discarded (DXS6797) because it was difficult to interpret. The mutation screening method provides results in 4 days, and when applied to 29 patients suspected of having XLAS, it identified mutations in 76% (22 of 29 patients). This study correlates COL4A5 mutations with effects at the mRNA level and suggests that mutations affecting mRNA splicing of the COL4A5 gene (41%; 9 of 22 patients) are more common than previously described. Many splicing mutations did not alter the canonical 5' and 3' splice sites. CONCLUSIONS: A more reliable linkage analysis and a simple, fast, and efficient mutation screening are now available for the genetic testing of patients with XLAS.
650    _2
$a kolagen typu IV $x genetika $7 D024141
650    _2
$a komplementární DNA $x genetika $7 D018076
650    _2
$a genetické testování $x metody $7 D005820
650    _2
$a vlasový folikul $x fyziologie $7 D018859
650    _2
$a lidé $7 D006801
650    _2
$a genetická vazba $x genetika $7 D008040
650    _2
$a mikrosatelitní repetice $x genetika $7 D018895
650    _2
$a dědičná nefritida $x diagnóza $x genetika $7 D009394
650    _2
$a RNA $x genetika $7 D012313
650    _2
$a sekvenční analýza DNA $x metody $7 D017422
700    1_
$a Ars, E. $7 gn_A_00008911
700    1_
$a Burset, M.
700    1_
$a Santin, S.
700    1_
$a Ruíz, P.
700    1_
$a Fernandez-Llama, P.
700    1_
$a Ballarin, J.
700    1_
$a Torra, R.
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 5, č. 6 (2007), s. 85 $x 1214-178X
787    18
$w bmc07505977 $i Recenze v: $t Komentář [k článku Molekulárně genetická diagnostika X-vázané formy Alportova syndromu]
856    41
$u https://www.postgradualninefrologie.cz/download/format/pdf/id/299/ $y plný text volně přístupný
910    __
$a ABA008 $b B 2318 $c 893 $y 1
990    __
$a 20080627115530 $b ABA008
991    __
$a 20081211073528 $b ABA008
999    __
$a ok $b bmc $g 621598 $s 474031
BAS    __
$a 3
BMC    __
$a 2007 $b 5 $c 6 $d 85 $i 1214-178X $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2008-6/mkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...